CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price, Forecast & Analysis

NYSEARCA:CANF • US13471N3008

4.65 USD
+0.21 (+4.73%)
At close: Feb 20, 2026
4.73 USD
+0.08 (+1.72%)
After Hours: 2/20/2026, 8:20:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

CANF Key Statistics, Chart & Performance

Key Statistics
Market Cap6.09M
Revenue(TTM)674.00K
Net Income(TTM)-7.88M
Shares1.31M
Float1.31M
52 Week High46.6
52 Week Low3.36
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-9.44
PEN/A
Fwd PEN/A
Earnings (Next)04-12
IPO2005-09-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
CANF short term performance overview.The bars show the price performance of CANF in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

CANF long term performance overview.The bars show the price performance of CANF in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CANF is 4.65 USD. In the past month the price increased by 11.78%. In the past year, price decreased by -87.15%.

CAN FITE BIOPHARMA LTD-ADR / CANF Daily stock chart

CANF Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CANF. When comparing the yearly performance of all stocks, CANF is a bad performer in the overall market: 95.66% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
CANF Full Technical Analysis Report

CANF Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CANF. CANF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CANF Full Fundamental Analysis Report

CANF Financial Highlights

Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -9.44. The EPS increased by 39.36% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -102.07%
ROE -188.34%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%34.22%
Sales Q2Q%-36.08%
EPS 1Y (TTM)39.36%
Revenue 1Y (TTM)-9.29%
CANF financials

CANF Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y13.95%
Revenue Next Year0%
CANF Analyst EstimatesCANF Analyst Ratings

CANF Ownership

Ownership
Inst Owners2.01%
Ins Owners0.01%
Short Float %N/A
Short Ratio0.02
CANF Ownership

CANF Latest News, Press Relases and Analysis

16 days ago - By: Chartmill - Mentions: DHX NINE AMSC LFVN ...
All CANF news

CANF Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.48396.512B
AMGN AMGEN INC16.63202.199B
GILD GILEAD SCIENCES INC16.97187.492B
VRTX VERTEX PHARMACEUTICALS INC23.39119.063B
REGN REGENERON PHARMACEUTICALS16.7882.713B
ALNY ALNYLAM PHARMACEUTICALS INC50.1944.834B
INSM INSMED INC N/A34.336B
NTRA NATERA INC N/A30.104B
BIIB BIOGEN INC12.6228.19B
UTHR UNITED THERAPEUTICS CORP16.0620.691B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About CANF

Company Profile

CANF logo image Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Company Info

CAN FITE BIOPHARMA LTD-ADR

10 Bareket Street, Kiryat Matalon, P.O. Box 7537

Petah Tikva 4951778 IL

CEO: Pnina Fishman

Employees: 5

CANF Company Website

CANF Investor Relations

Phone: 97239241114

CAN FITE BIOPHARMA LTD-ADR / CANF FAQ

Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.


What is the stock price of CAN FITE BIOPHARMA LTD-ADR today?

The current stock price of CANF is 4.65 USD. The price increased by 4.73% in the last trading session.


What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?

CANF does not pay a dividend.


How is the ChartMill rating for CAN FITE BIOPHARMA LTD-ADR?

CANF has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of CANF stock?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 6.09M USD. This makes CANF a Nano Cap stock.